HIH
EUCR

HRS Investment Holdings’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

HRS Investment Holdings’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-74,000
Closed -$722K – 62
2021
Q4 		$722K Buy
+74,000
New +$725K 0.24% 108

Other funds holding EUCR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ECU
Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

HRS Investment Holdings's EUCR Position: Q1 2022 in Review

HRS Investment Holdings sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q1 2022, closing a stake of 74,000 shares — an estimated $722K sold.

HRS Investment Holdings first reported a position in EUCR in Q4 2021 and held it in 1 quarter. The position peaked at $722K in Q4 2021. 39 funds tracked by Wall St. Rank hold EUCR as of Q1 2022.

  • HRS Investment Holdings reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • HRS Investment Holdings sold 74,000 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q1 2022, an estimated $722K.
  • HRS Investment Holdings first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 1 quarter.
  • HRS Investment Holdings's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $722K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q1 2022.

Based on HRS Investment Holdings's 13F filing for Q1 2022, filed 16 May 2022.